Published June 27, 2022 | Version 2.3.6
Journal article Open

Kriya® Hops CBD for Anxiety and Sleep Disorders: A Retrospective Clinical Study in an Outpatient Psychiatric Population

Authors/Creators

  • 1. Peak Health Center
  • 2. ImmunAG LLP

Description

Background: Cannabidiol (CBD) from hops (Humulus lupulus)—known as Kriya® Hops CBD—is a non-cannabis–derived cannabidiol product with high bioactivity (96.3%). Many psychiatric patients seek natural, non-cannabis alternatives foranxiety and insomnia. This study evaluates the clinical effects of Kriya® Hops CBD as an adjunct to treatment as usual in a real-world psychiatric setting.

Methods: A retrospective chart review was conducted at a large integrative psychiatric clinic in Fort Collins, Colorado. Adult patients with clinician-diagnosed anxiety or sleep disorders who received Kriya® Hops CBD for ≥1 month were included.

Outcomes were measured monthly using the Hamilton Anxiety Rating Scale (HAM-A) and the Pittsburgh Sleep Quality Index (PSQI). Descriptive statistics were performed.

Results: The final sample consisted of 143 adults (94 anxiety; 49 sleep). Most received 25 mg/day of Kriya® Hops CBD. At the first monthly follow-up, 79.2% showed improvement in anxiety and 66.7% showed improvement in sleep. Significant improvement occurred in 15.3% (anxiety) and 25.0% (sleep). Anxiety improvements were rapid and sustained over 3 months, while sleep improvements were present but less stable. Treatment was well tolerated with minimal side effects.

Conclusion: Kriya® Hops CBD demonstrated favorable tolerability and clinically meaningful improvements in anxiety and sleep within a naturalistic psychiatric setting. Compared to existing literature on cannabis-derived CBD, benefits were observed at substantially lower doses, suggesting higher clinical potency. Prospective controlled trials are warranted.

Files

Kriya®_Hops_CBD_for_Anxiety_and_Sleep_Disorders.pdf

Files (314.8 kB)

Additional details

Related works

Is cited by
Publication: 2577-6541 (ISSN)

Dates

Submitted
2022-01-18
Accepted
2022-04-22

Software

Repository URL
https://datamanagement.hms.harvard.edu/share-publish
Programming language
Python
Development Status
Active

References

  • Devinsky O, Cilio MR, Cross H, et al. Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia. 2014;55(6):791–802. doi:10.1111/epi.12631
  • Abrams DI, Jay CA, Shade SB, et al. Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology. 2007;68(7):515–521. doi:10.1212/01.wnl.0000253187.66183.9c
  • Devinsky O, Cross JH, Laux L, et al.; Cannabidiol in Dravet Syndrome Study Group. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med. 2017;376(21):2011–2020. doi:10.1056/NEJMoa1611618
  • Zuardi AW, Rodrigues NP, Silva AL, et al. Inverted U-shaped dose-response curve of the anxiolytic effect of cannabidiol during public speaking in real life. Front Pharmacol. 2017;8:259. doi:10.3389/fphar.2017.00259
  • Bergamaschi MM, Queiroz RH, Chagas MH, et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacology. 2011;36(6):1219–1226. doi:10.1038/npp.2011.6
  • Guimarães FS, Chiaretti TM, Graeff FG, Zuardi AW. Antianxiety effect of cannabidiol in the elevated plus-maze. Psychopharmacology (Berl). 1990;100(4):558–559. doi:10.1007/BF02244012
  • Zhornitsky S, Potvin S. Cannabidiol in humans—the quest for therapeutic targets. Pharmaceuticals (Basel). 2012;5(5):529–552. doi:10.3390/ph5050529
  • Zuardi AW, Guimarães FS, Moreira AC. Effect of cannabidiol on plasma prolactin, growth hormone and cortisol in human volunteers. Braz J Med Biol Res. 1993;26(2):213–217.
  • Iffland K, Grotenhermen F. An update on safety and side effects of cannabidiol: a review of clinical data and relevant animal studies. Cannabis Cannabinoid Res. 2017;2(1):139–154. doi:10.1089/can.2016.0034
  • Loflin MJE, Earleywine M, Farmer S, Slavin M, Luba R, Bonn-Miller MO. Placebo effects of edible cannabis: reported intoxication effects at a 30-minute delay. J Psychoactive Drugs. 2017;49(5):393–397. doi:10.1080/02791072.2017.1354409
  • Drug Enforcement Administration (DEA). Clarification of the new drug code (7350) for marijuana extract. Diversion Control Division; 2017. Available at: https://www.deadiversion.usdoj.gov/schedules/marijuana/m_extract_7350.html Accessed August 7, 2018.
  • Cushing D, Kristipat S, Shastri R, Joseph B. Measuring the bioactivity of phytocannabinoid cannabidiol from cannabis sources and a novel non-cannabis source. Journal of Medical Phyto Research. 2023;1:Article 2:8–23. doi:10.31013/1002b